Indication

Adamantinous Craniopharyngioma

1 clinical trial

1 product

Clinical trial

Phase 2 Study of the MEK Inhibitor MEKTOVI® (Binimetinib) for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

Status: Recruiting, Estimated PCD: 2025-04-10

Product